{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:48:09Z","timestamp":1790426889774,"version":"4.1.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"849","license":[{"start":{"date-parts":[[1996,7,1]],"date-time":"1996-07-01T00:00:00Z","timestamp":836179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1996,7,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>The long-acting analogues of somatostatin have an established place in the medical treatment of patients with neuroendocrine tumours. They act through binding with specific, high-affinity membrane receptors. Somatostatin analogue therapy is an effective and safe treatment for most growth hormone and thyrothropin-secreting pituitary adenomas. The potential therapeutic consequences of the presence of somatostatin receptors on clinically \u2018nonfunctioning\u2019 pituitary tumours are still uncertain. Somatostatin analogues are not useful in the treatment of patients with prolactinomas, or adrenocorticotropin (ACTH)-secreting adenomas. However, the somatostatin analogue octreotide suppressed pathological ACTH release in some patients with Nelson\u2019s syndrome and ACTH and cortisol secretion in several patients with Cushing\u2019s syndrome caused by ectopic ACTH secretion. Somatostatin analogues are effective in the sympatomatic treatment of most (metastatic) pancreatic islet cell tumours and most (metastatic) carcinoids. In some of these patients, they also induce tumour stabilisation or reduction. In some patients with (metastatic) medullary thyroid carcinomas, continuous treatment with very high doses of octreotide can be of temporary relief. The clinical effectiveness of somatostatin analogues in patients with small cell lung cancer is currently under investigation. Long-term therapy with somatostatin analogues of catecholamine-secreting (malignant) paragangliomas and phaeochromocytomas has not shown clinical benefits.<\/jats:p>","DOI":"10.1136\/pgmj.72.849.403","type":"journal-article","created":{"date-parts":[[2008,12,29]],"date-time":"2008-12-29T21:49:00Z","timestamp":1230587340000},"page":"403-408","source":"Crossref","is-referenced-by-count":33,"title":["Somatostatin analogue treatment of neuroendocrine tumours"],"prefix":"10.1093","volume":"72","author":[{"given":"W W","family":"de Herder","sequence":"first","affiliation":[{"name":"Department of Internal Medicine III, University Hospital , 3015 GD Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"van der Lely","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital , 3015 GD Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S W","family":"Lamberts","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital , 3015 GD Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[1996,7,1]]},"reference":[{"key":"ref_1","first-page":"1495","article-title":"Somatostatin (first of two parts)","volume":"309","author":"Reichlin, S.","year":"1983","unstructured":"Reichlin S. Somatostatin (first of two parts). N Engl Med 1983; 309: 1495-501.","journal-title":"N Engl Med"},{"key":"ref_2","first-page":"1556","article-title":"Somatostatin (second of two parts)","volume":"309","author":"Reichlin, S.","year":"1983","unstructured":"Reichlin S. Somatostatin (second of two parts). N Engl Jf Med 1983; 309: 1556-63.","journal-title":"N Engl Jf Med"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1056\/NEJM199310213291708","article-title":"Neuroendocrine-immune interactions","volume":"329","author":"Reichlin, S.","year":"1993","unstructured":"Reichlin S. Neuroendocrine-immune interactions. N Engl J Med 1993; 329: 1246-53.","journal-title":"N Engl J Med"},{"key":"ref_4","first-page":"145","article-title":"Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide","volume":"79","author":"Morange, I.; De Boisvilliers, F.; Chanson, P.","year":"1994","unstructured":"Morange I, De Boisvilliers F, Chanson P, et al. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide. J Clin Endocrinol Metab 1994; 79: 145-51.","journal-title":"J Clin Endocrinol Metab"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1530\/eje.0.1320320","article-title":"Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide","volume":"132","author":"Caron, P.; Cogne, M.; Gusthiot-Joudet, B.; Wakim, S.; Catus, F.; Bayard, F.","year":"1995","unstructured":"Caron P, Cogne M, Gusthiot-Joudet B, Wakim S, Catus F, Bayard F. Intramuscular injections of slow-release lanreotide (BIM 23014) in acromegalic patients previously treated with continuous subcutaneous infusion of octreotide (SMS 201-995). Eur J Endocrinol 1995; 132: 320-5.","journal-title":"Eur J Endocrinol"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0960-0760(92)90184-K","article-title":"Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications","volume":"43","author":"Reubi, J.C.; Laissue, J.; Krenning, E.; Lamberts, S.W.","year":"1992","unstructured":"Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol 1992; 43: 27-35.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1006\/frne.1993.1002","article-title":"Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy","volume":"14","author":"Lamberts, S.W.; Hofland, L.J.; de Herder, W.W.; Kwekkeboom, D.J.; Reubi, J.C.; Krenning, E.P.","year":"1993","unstructured":"Lamberts SW, Hofland LJ, de Herder WW, Kwekkeboom DJ, Reubi JC, Krenning EP. Octreotide and related somatostatin analogs in the diagnosis and treatment of pituitary disease and somatostatin receptor scintigraphy. Front Neuroendocrinol 1993; 14: 27-55.","journal-title":"Front Neuroendocrinol"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1210\/edrv-9-4-417","article-title":"The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors","volume":"9","author":"Lamberts, S.W.","year":"1988","unstructured":"Lamberts SW. The role of somatostatin in the regulation of anterior pituitary hormone secretion and the use of its analogs in the treatment of human pituitary tumors. Endocr Rev 1988; 9: 417-36.","journal-title":"Endocr Rev"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/edrv-12-4-450","article-title":"The role of somatostatin and its analogs in the diagnosis and treatment of tumors","volume":"12","author":"Lamberts, S.W.; Krenning, E.P.; Reubi, J.C.","year":"1991","unstructured":"Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450-82.","journal-title":"Endocr Rev"},{"key":"ref_10","first-page":"245","article-title":"Role in tumour treatment and diagnosis","volume":"1","author":"Lamberts, S.W.; Krenning, E.P.; Somatostatin, Reubi J.C.","year":"1993","unstructured":"Lamberts SW, Krenning EP, Reubi JC. Somatostatin. Role in tumour treatment and diagnosis. Endocr Rev Monogr 1993; 1: 245-6.","journal-title":"Endocr Rev Monogr"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/0003-4819-117-9-711","article-title":"Octreotide treatment of acromegaly A randomized, multicenter study","volume":"117","author":"Ezzat, S.; Snyder, P.J.; Young, W.F.","year":"1992","unstructured":"Ezzat S, Snyder PJ, Young WF, et al. Octreotide treatment of acromegaly A randomized, multicenter study. Ann Intern Med 1992; 117: 711-8.","journal-title":"Ann Intern Med"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0026-0495(94)90199-6","article-title":"Insulin-like growth factors (IGF)-I and -II and IGF binding protein-i, -2, and -3 in patients with acromegaly before and after adenomectomy","volume":"43","author":"Jorgensen, J.O.; Moller, N.; Moller, J.; Weeke, J.; Blum, W.F.","year":"1994","unstructured":"Jorgensen JO, Moller N, Moller J, Weeke J, Blum WF. Insulin-like growth factors (IGF)-I and -II and IGF binding protein-i, -2, and -3 in patients with acromegaly before and after adenomectomy. Metabolism 1994; 43: 579-83.","journal-title":"Metabolism"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/eje.0.1330195","article-title":"Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly","volume":"133","author":"de Herder WW; P, Uitterlinden; van der Lely AJ; LJ, Hofland; SWJ, Lamberts","year":"1995","unstructured":"de Herder WW, Uitterlinden P, van der Lely AJ, Hofland LJ, Lamberts SWJ. Octreotide, but not bromocriptine, increases circulating insulin-like growth factor binding protein 1 levels in acromegaly. Eur J Endocrinol 1995; 133: 195-9.","journal-title":"Eur J Endocrinol"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"236","DOI":"10.7326\/0003-4819-119-3-199308010-00010","article-title":"Octreotide therapy for thyroid-stimulating hormonesecreting pituitary adenomas A follow-up of 52 patients","volume":"119","author":"Chanson, P.; Weintraub, B.D.; Harris, A.G.","year":"1993","unstructured":"Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid-stimulating hormonesecreting pituitary adenomas A follow-up of 52 patients. Ann Intern Med 1993; 119: 236-40.","journal-title":"Ann Intern Med"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0002-9343(94)90059-0","article-title":"Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion","volume":"96","author":"de Herder WW; EP, Krenning; CD, Malchoff","year":"1994","unstructured":"de Herder WW, Krenning EP, Malchoff CD, et al. Somatostatin receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med 1994; 96: 305-12.","journal-title":"Am J Med"},{"key":"ref_16","first-page":"17","article-title":"A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome","volume":"78","author":"Lamberts, S.W.; de Herder, W.W.; Krenning, E.P.; Reubi, J.C.","year":"1994","unstructured":"Lamberts SW, de Herder WW, Krenning EP, Reubi JC. A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. J Clin Endocninol Metab 1994; 78: 17-9.","journal-title":"J Clin Endocninol Metab"},{"issue":"1","key":"ref_17","first-page":"6","article-title":"Current tools in the diagnosis of pituitary tumours","volume":"129","author":"Lamberts, S.W.; de Herder, W.W.; Kwekkeboom, D.J.; vd Lely, A.J.; Nobels, F.R.; Krenning, E.P.","year":"1993","unstructured":"Lamberts SW, de Herder WW, Kwekkeboom DJ, vd Lely AJ, Nobels FR, Krenning EP. Current tools in the diagnosis of pituitary tumours. Acta Endocninol Copenh 1993; 129 suppl 1: 6-12.","journal-title":"Acta Endocninol Copenh"},{"key":"ref_18","first-page":"1310","article-title":"Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro","volume":"75","author":"de Bruin TW; DJ, Kwekkeboom; van't Verlaat JW","year":"1992","unstructured":"de Bruin TW, Kwekkeboom DJ, van't Verlaat JW, et al. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin EndocrinolMetab 1992; 75: 1310-7.","journal-title":"J Clin EndocrinolMetab"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000183785","article-title":"Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas","volume":"40","author":"Merola, B.; Colao, A.; Ferone, D.","year":"1993","unstructured":"Merola B, Colao A, Ferone D, et al. Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. Horm Res 1993; 40: 149-55.","journal-title":"Horm Res"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1987.5.10.1502","article-title":"An odyssey in the land of small tumors","volume":"5","author":"Moertel, C.G.","year":"1987","unstructured":"Moertel CG. An odyssey in the land of small tumors. J Clin Oncol 1987; 5: 1502-22.","journal-title":"J Clin Oncol"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jcem-73-1-1","article-title":"The use of the longacting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors","volume":"73","author":"Wynick, D.; Bloom, SR","year":"1991","unstructured":"Wynick D, Bloom SR. The use of the longacting somatostatin analog octreotide in the treatment of gut neuroendocrine tumors.J Clin EndocrinolMetab 1991; 73: 1-3.","journal-title":"J Clin EndocrinolMetab"},{"issue":"244","key":"ref_22","article-title":"Neuroendocrine embryology and the APUD concept","volume":"229","author":"Pearse, A.G.; Takor, T.T.","year":"1976","unstructured":"Pearse AG, Takor TT. Neuroendocrine embryology and the APUD concept. Clin Endocrinol 1976; 5 Suppl: 229S-244S.","journal-title":"Clin Endocrinol"},{"key":"ref_23","first-page":"385","article-title":"Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide","volume":"30","author":"Wynick, D.; Anderson, J.V.; Williams, S.J.; Bloom, SR","year":"2019","unstructured":"Wynick D, Anderson JV, Williams SJ, Bloom SR. Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201995). Clin Endocrinol 1989; 30: 385-8.","journal-title":"Clin Endocrinol"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/02841868909111218","article-title":"Therapeutic considerations for the malignant carcinoid syndrome","volume":"28","author":"Kvols, L.K.","year":"1989","unstructured":"Kvols LK. Therapeutic considerations for the malignant carcinoid syndrome. Acta Oncol 1989; 28: 433-8.","journal-title":"Acta Oncol"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/02841869309083912","article-title":"Metastatic carcinoid tumors and the malignant carcinoid syndrome","volume":"32","author":"Kvols, L.K.; Reubi, J.C.","year":"1993","unstructured":"Kvols LK, Reubi JC. Metastatic carcinoid tumors and the malignant carcinoid syndrome. Acta Oncol 1993; 32: 197-201.","journal-title":"Acta Oncol"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-2007-1010946","article-title":"Effect of a somatostatin analog (SMS 201-995) in perfusion on basal and pentagastrin-stimulated calcitonin levels in medullary thyroid carcinoma","volume":"20","author":"Modigliani, E.; Chayvialle, J.A.; Cohen, R.","year":"1988","unstructured":"Modigliani E, Chayvialle JA, Cohen R, et al. Effect of a somatostatin analog (SMS 201-995) in perfusion on basal and pentagastrin-stimulated calcitonin levels in medullary thyroid carcinoma. Horm Metab Res 1988; 20: 773-5.","journal-title":"Horm Metab Res"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2265.1990.tb00490.x","article-title":"Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide","volume":"33","author":"Mahler, C.; Verhelst, J.; de Longueville, M.; Harris, A.","year":"1990","unstructured":"Mahler C, Verhelst J, de Longueville M, Harris A. Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 1990; 33: 261-9.","journal-title":"Clin Endocrinol"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2265.1992.tb00955.x","article-title":"Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma","volume":"36","author":"Modigliani, E.; Cohen, R.; Joannidis, S.","year":"1992","unstructured":"Modigliani E, Cohen R, Joannidis S, et al. Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma. Clin Endocrinol 1992; 36: 183-6.","journal-title":"Clin Endocrinol"},{"key":"ref_29","first-page":"44","article-title":"The use of octreotide in the treatment of medullary thyroid carcinoma","volume":"27","author":"Frank-Raue, K.; Ziegler, R.; Raue, F.","year":"1993","unstructured":"Frank-Raue K, Ziegler R, Raue F. The use of octreotide in the treatment of medullary thyroid carcinoma. Horm Metab Res 1993; 27 (suppl): 44-7.","journal-title":"Horm Metab Res"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"the Rotterdam experience with more than 1000 patients","volume":"20","author":"Krenning, E.P.; Kwekkeboom, D.J.; Bakker, W.H.","year":"1993","unstructured":"Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [11 lIn-DTPA-D-Phel]-and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-31.","journal-title":"Eur J Nucl Med"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/72\/849\/403\/50220001\/postgradmedj-72-403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/72\/849\/403\/50220001\/postgradmedj-72-403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T05:05:23Z","timestamp":1683781523000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/72\/849\/403\/7046668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,7,1]]},"references-count":30,"journal-issue":{"issue":"849","published-online":{"date-parts":[[1996,7,1]]},"published-print":{"date-parts":[[1996,7,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.72.849.403","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[1996,7]]},"published":{"date-parts":[[1996,7,1]]}}}